{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:35Z","timestamp":1792783175622,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Taiwan Continence Society","award":["2020-06-A"],"award-info":[{"award-number":["2020-06-A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05220-2","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:32:35Z","timestamp":1780284755000},"page":"4757-4765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of behavioral therapy and different dosages of mirabegron for the treatment of male overactive bladder patients"],"prefix":"10.1007","volume":"58","author":[{"given":"You-Ting","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Chi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"Suppl 3","key":"5220_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1464-410x.2000.tb16953.x","volume":"85","author":"AW Thomas","year":"2000","unstructured":"Thomas AW, Abrams P (2000) Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 85(Suppl 3):57\u201368. https:\/\/doi.org\/10.1111\/j.1464-410x.2000.tb16953.x. (discussion 70\u201351)","journal-title":"BJU Int"},{"issue":"6","key":"5220_CR2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306\u20131314. https:\/\/doi.org\/10.1016\/j.eururo.2006.09.019. (discussion 1314\u20131305)","journal-title":"Eur Urol"},{"issue":"6","key":"5220_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327\u2013336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4","journal-title":"World J Urol"},{"issue":"1","key":"5220_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/luts.12193","volume":"11","author":"YC Chuang","year":"2019","unstructured":"Chuang YC, Liu SP, Lee KS, Liao L, Wang J, Yoo TK, Chu R, Sumarsono B (2019) Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms 11(1):48\u201355. https:\/\/doi.org\/10.1111\/luts.12193","journal-title":"Low Urin Tract Symptoms"},{"key":"5220_CR5","volume-title":"EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS)","author":"European Association of Urology","year":"2024","unstructured":"European Association of Urology (2024) EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), 2024 edition edn. EAU Guidelines Office, Arnhem, The Netherlands","edition":"2024 edition ed"},{"issue":"1","key":"5220_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/ju.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, Linder BJ, Reynolds WS, Rovner ES, Souter L, Suskind AM, Takacs E, Welk B, Smith AL (2024) The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol 212(1):11\u201320. https:\/\/doi.org\/10.1097\/ju.0000000000003985","journal-title":"J Urol"},{"issue":"1","key":"5220_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.urols.2014.12.003","volume":"26","author":"C-C Wang","year":"2015","unstructured":"Wang C-C, Liao C-H, Kuo H-C (2015) Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder. Urol Sci 26(1):7\u201316. https:\/\/doi.org\/10.1016\/j.urols.2014.12.003","journal-title":"Urol Sci"},{"issue":"9","key":"5220_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/11592790-000000000-00000","volume":"34","author":"MG Oefelein","year":"2011","unstructured":"Oefelein MG (2011) Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 34(9):733\u2013754. https:\/\/doi.org\/10.2165\/11592790-000000000-00000","journal-title":"Drug Saf"},{"issue":"3","key":"5220_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.bjp.0702358","volume":"126","author":"Y Igawa","year":"1999","unstructured":"Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE (1999) Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126(3):819\u2013825. https:\/\/doi.org\/10.1038\/sj.bjp.0702358","journal-title":"Br J Pharmacol"},{"issue":"3","key":"5220_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","volume":"288","author":"M Takeda","year":"1999","unstructured":"Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288(3):1367\u20131373","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"5220_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamainternmed.2019.6398","volume":"180","author":"KL Burgio","year":"2020","unstructured":"Burgio KL, Kraus SR, Johnson TM 2nd, Markland AD, Vaughan CP, Li P, Redden DT, Goode PS (2020) Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med 180(3):411\u2013419. https:\/\/doi.org\/10.1001\/jamainternmed.2019.6398","journal-title":"JAMA Intern Med"},{"issue":"8","key":"5220_CR12","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/nau.24158","volume":"38","author":"A Kasman","year":"2019","unstructured":"Kasman A, Stave C, Elliott CS (2019) Combination therapy in overactive bladder-untapped research opportunities: a systematic review of the literature. Neurourol Urodyn 38(8):2083\u20132092. https:\/\/doi.org\/10.1002\/nau.24158","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"5220_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5213\/inj.2346148.074","volume":"27","author":"CC Lin","year":"2023","unstructured":"Lin CC, Kuo HC, Li JR, Chuang YC (2023) Comparative study between behavior therapy and behavior therapy plus Mirabegron 50 mg in sexually active men with bothersome overactive bladder symptoms - a multicenter, randomized study. Int Neurourol J 27(3):182\u2013191. https:\/\/doi.org\/10.5213\/inj.2346148.074","journal-title":"Int Neurourol J"},{"issue":"7","key":"5220_CR14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s11255-018-1907-9","volume":"50","author":"YC Shen","year":"2018","unstructured":"Shen YC, Wang HJ, Chuang YC (2018) Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice. Int Urol Nephrol 50(7):1219\u20131226. https:\/\/doi.org\/10.1007\/s11255-018-1907-9","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"5220_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13537","volume":"74","author":"YC Shen","year":"2020","unstructured":"Shen YC, Wang HJ, Lee WC, Chen CH, Chuang YC (2020) Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder. Int J Clin Pract 74(9):e13537. https:\/\/doi.org\/10.1111\/ijcp.13537","journal-title":"Int J Clin Pract"},{"issue":"2","key":"5220_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome\u2013overactive bladder symptom score. Urology 68(2):318\u2013323. https:\/\/doi.org\/10.1016\/j.urology.2006.02.042","journal-title":"Urology"},{"issue":"2","key":"5220_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","volume":"16","author":"O Yamaguchi","year":"2009","unstructured":"Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, Obara K, Gotoh M, Igawa Y, Seki N, Yoshida M, Neurogenic Bladder S (2009) Clinical guidelines for overactive bladder. Int J Urol 16(2):126\u2013142. https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02177.x","journal-title":"Int J Urol"},{"issue":"6","key":"5220_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00192-010-1100-x","volume":"21","author":"KL Burgio","year":"2010","unstructured":"Burgio KL, Kraus SR, Borello-France D, Chai TC, Kenton K, Goode PS, Xu Y, Kusek JW, Urinary Incontinence Treatment N (2010) The effects of drug and behavior therapy on urgency and voiding frequency. Int Urogynecol J 21(6):711\u2013719. https:\/\/doi.org\/10.1007\/s00192-010-1100-x","journal-title":"Int Urogynecol J"},{"issue":"4","key":"5220_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0269215510385481","volume":"25","author":"S Kaya","year":"2011","unstructured":"Kaya S, Akbayrak T, Beksa\u00e7 S (2011) Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil 25(4):327\u2013338. https:\/\/doi.org\/10.1177\/0269215510385481","journal-title":"Clin Rehabil"},{"issue":"6","key":"5220_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3346\/jkms.2006.21.6.1060","volume":"21","author":"C Song","year":"2006","unstructured":"Song C, Park JT, Heo KO, Lee KS, Choo MS (2006) Effects of bladder training and\/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 21(6):1060\u20131063. https:\/\/doi.org\/10.3346\/jkms.2006.21.6.1060","journal-title":"J Korean Med Sci"},{"issue":"2","key":"5220_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000109285","volume":"65","author":"SW Kim","year":"2008","unstructured":"Kim SW, Song SH, Ku JH (2008) Bladder training versus combination of propiverine with bladder training for female urinary frequency. A prospective, randomized, comparative study. Gynecol Obstet Invest 65(2):123\u2013127. https:\/\/doi.org\/10.1159\/000109285","journal-title":"Gynecol Obstet Invest"},{"issue":"4","key":"5220_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1742-1241.2008.01714.x","volume":"62","author":"MB Chancellor","year":"2008","unstructured":"Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G, Delconte A (2008) A comparison of the efficacy of darifenacin alone vs. darifenacin plus a behavioural modification programme upon the symptoms of overactive bladder. Int J Clin Pract 62(4):606\u2013613. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01714.x","journal-title":"Int J Clin Pract"},{"issue":"8","key":"5220_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1464-410X.2009.08910.x","volume":"105","author":"A Mattiasson","year":"2010","unstructured":"Mattiasson A, Masala A, Morton R, Bolodeoku J (2010) Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. BJU Int 105(8):1126\u20131135. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08910.x","journal-title":"BJU Int"},{"issue":"6","key":"5220_CR24","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/j.juro.2009.02.028","volume":"181","author":"CG Klutke","year":"2009","unstructured":"Klutke CG, Burgio KL, Wyman JF, Guan Z, Sun F, Berriman S, Bavendam T (2009) Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol 181(6):2599\u20132607. https:\/\/doi.org\/10.1016\/j.juro.2009.02.028","journal-title":"J Urol"},{"issue":"2","key":"5220_CR25","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.juro.2010.03.141","volume":"184","author":"KL Burgio","year":"2010","unstructured":"Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM 2nd, Redden DT (2010) Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. J Urol 184(2):598\u2013603. https:\/\/doi.org\/10.1016\/j.juro.2010.03.141","journal-title":"J Urol"},{"issue":"1","key":"5220_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/nau.10167","volume":"23","author":"RJ Millard","year":"2004","unstructured":"Millard RJ (2004) Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn 23(1):48\u201353. https:\/\/doi.org\/10.1002\/nau.10167","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"5220_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1464-410x.2003.03076.x","volume":"91","author":"A Mattiasson","year":"2003","unstructured":"Mattiasson A, Blaakaer J, H\u00f8ye K, Wein AJ (2003) Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91(1):54\u201360. https:\/\/doi.org\/10.1046\/j.1464-410x.2003.03076.x","journal-title":"BJU Int"},{"issue":"4","key":"5220_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1532-5415.2000.tb04692.x","volume":"48","author":"KL Burgio","year":"2000","unstructured":"Burgio KL, Locher JL, Goode PS (2000) Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 48(4):370\u2013374. https:\/\/doi.org\/10.1111\/j.1532-5415.2000.tb04692.x","journal-title":"J Am Geriatr Soc"},{"key":"5220_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s0084-4071(09)79300-5","volume":"2009","author":"ES Rovner","year":"2009","unstructured":"Rovner ES (2009) Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: A randomized trial. Yearb Urol 2009:74\u201376. https:\/\/doi.org\/10.1016\/s0084-4071(09)79300-5","journal-title":"Yearb Urol"},{"issue":"5","key":"5220_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1359105319891629","volume":"25","author":"VL La Rosa","year":"2020","unstructured":"La Rosa VL, Duarte de Campos da Silva T, Rosa de Oliveira A, Marques Cerentini T, Viana da Rosa P, Telles da Rosa LH (2020) Behavioral therapy versus drug therapy in individuals with idiopathic overactive bladder: A systematic review and meta-analysis. J Health Psychol 25(5):573\u2013585. https:\/\/doi.org\/10.1177\/1359105319891629","journal-title":"J Health Psychol"},{"issue":"5","key":"5220_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/nau.24692","volume":"40","author":"CD Miller","year":"2021","unstructured":"Miller CD, Monaghan TF, Robins DJ, Weiss JP (2021) Does traditional pharmacotherapy augment behavioral modification in the treatment of nocturia? Neurourol Urodyn 40(5):1133\u20131139. https:\/\/doi.org\/10.1002\/nau.24692","journal-title":"Neurourol Urodyn"},{"key":"5220_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.10.001","author":"TM Johnson 2nd","year":"2016","unstructured":"Johnson TM 2nd, Vaughan CP, Goode PS, Bliwise DL, Markland AD, Huisingh C, Redden DT, McGwin G, Eisenstein R, Ouslander JG, Issa M, Burgio KL (2016) Pilot results from a randomized trial in men comparing alpha-adrenergic antagonist versus behavior and exercise for nocturia and sleep. Clin Ther. https:\/\/doi.org\/10.1016\/j.clinthera.2016.10.001","journal-title":"Clin Ther"},{"issue":"4","key":"5220_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.urology.2011.06.020","volume":"78","author":"M Gotoh","year":"2011","unstructured":"Gotoh M, Homma Y, Yokoyama O, Nishizawa O (2011) Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology 78(4):768\u2013773. https:\/\/doi.org\/10.1016\/j.urology.2011.06.020","journal-title":"Urology"},{"issue":"5","key":"5220_CR34","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/s0022-5347(01)66780-6","volume":"154","author":"MJ Barry","year":"1995","unstructured":"Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, Lepor H (1995) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154(5):1770\u20131774. https:\/\/doi.org\/10.1016\/s0022-5347(01)66780-6","journal-title":"J Urol"},{"issue":"12","key":"5220_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032795","volume":"9","author":"MH Blanker","year":"2019","unstructured":"Blanker MH, Alma HJ, Devji TS, Roelofs M, Steffens MG, van der Worp H (2019) Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open 9(12):e032795. https:\/\/doi.org\/10.1136\/bmjopen-2019-032795","journal-title":"BMJ Open"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05220-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05220-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05220-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:17:14Z","timestamp":1792765034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05220-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["5220"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05220-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All interventions performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}